Increase in Fibrinolytic Activity after Erythropoietin Therapy

Please copy the URL and add it into your RSS Feed Reader.

Thromb Haemost 1992; 67(02): 284
DOI: 10.1055/s-0038-1648429

Letters to the Editor

Schattauer GmbH Stuttgart

Authors

Jolanta Szewczuk

Department of Nephrology, Medical School, Zurawia 14, 15-540 Bialystok, Poland
Maria Mazerska

Department of Nephrology, Medical School, Zurawia 14, 15-540 Bialystok, Poland
Jacek Malyszko

Department of Nephrology, Medical School, Zurawia 14, 15-540 Bialystok, Poland
Marek Kalinowski

Department of Nephrology, Medical School, Zurawia 14, 15-540 Bialystok, Poland
Michal Mysliwiec

Department of Nephrology, Medical School, Zurawia 14, 15-540 Bialystok, Poland

Received 17 June 1991

Accepted after revision 09 August 1991

Publication Date:
02 July 2018 (online)

References
1 Casati C, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 1987; 295: 1017-1020

Reference Link Ris
Crossref PubMed Search in Google Scholar
2 Gordge MP, Leaker B, Patel A, Oviasu E, Cameron JS, Neild GH. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatis activation. Thromb Res 1990; 57: 171-182

Reference Link Ris
Crossref PubMed Search in Google Scholar
3 Chmielewska JN, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1985; 32: 482-485

Reference Link Ris
PubMed Search in Google Scholar